Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-2-fluoro-2-deoxy-D-glucose
- Development stage
- Unknown
- Lead developer
- Eastern Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) is a radiopharmaceutical glucose analog used in positron emission tomography (PET) imaging. Developed and produced locally by Eastern Health in Newfoundland and Labrador, Canada, this specific formulation is intended to improve patient access to diagnostic imaging within the province. The molecule is transported into cells by glucose transporters (GLUTs) and subsequently phosphorylated by hexokinase. Due to the substitution of a hydroxyl group with a fluorine-18 isotope at the C-2 position, the resulting 18F-FDG-6-phosphate cannot be further metabolized via glycolysis and remains trapped within the cell. This metabolic trapping allows for the visualization and quantification of glucose consumption in tissues, making it a vital tool for the diagnosis and staging of various conditions, including malignant tumors, neurological disorders, and inflammatory diseases.
- Other names
- fludeoxyglucose F 182-deoxy-2-(18F)fluoro-D-glucosefluorodeoxyglucose
02
Targets
GLUT (Glucose transporter family)GCK (Glucokinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on 18F-2-fluoro-2-deoxy-D-glucose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-2-fluoro-2-deoxy-D-glucose.